Sci-B-Vac is a third-generation licensed hepatitis B ('HBV') vaccine currently approved for use in Israel and in 14 other countries. Sci-B-Vac has demonstrated safety and efficacy in over 300,000 patients.

In contrast to some current hepatitis B vaccines, which contain only one surface antigen (the S antigen), Sci-B-Vac contains the S antigen and the pre-S1 and pre-S2 surface antigens. The composition of Sci-B-Vac may provide more opportunities for the immune system to respond with antibodies that can recognize one or more components of the hepatitis B virus.

According to the World Health Organization ('WHO'), globally, 240 million people are chronically infected with hepatitis B and more than 780,000 people die every year due to complications related to the virus, including cirrhosis and liver cancer. Learn more about Sci-B-Vac »

Sci-B-Vac Highlights

VBI Vaccines Inc. published this content on 19 July 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 July 2016 12:40:01 UTC.

Original documenthttp://www.vbivaccines.com/about/

Public permalinkhttp://www.publicnow.com/view/EFAE1C391A24AC0266EC42FE2E72FE4B009CD3C0